Revolution Medicines (RVMD) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Key numbers
- Reported EPS
- -$3.06
- Estimate
- -$2.06
- Surprise
- -48.8%
- Score today
- 4.8/10
Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.
How the report landed
Revolution Medicines (RVMD) reported a wider loss than forecast — diluted EPS of -$3.06 against the -$2.06 estimate (a 48.8% shortfall).
Where TrendMatrix's rating stands now
TrendMatrix currently rates RVMD Sell at 4.8/10; no pre/post engine snapshot brackets this report.
0 of the last 4 quarters beat the estimate; this quarter's -48.8% surprise compares with a -26.6% four-quarter average. Next scheduled report: 2026-11-04.
What argues against it
- Concentration risk — Pipeline: product candidates (no approved products)
- Concentration risk — Supplier: CDMOs
- Quality below floor (1.5 < 4.0)
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $210.50
- Price target
- $225.42
- Stop
- $195.32
- Upside to target
- +7.1%
- Reward-to-risk
- 0.9:1
Model outputs from TrendMatrix’s engine as of 2026-09-05 — shown for context, not personalized investment advice.
RVMD at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $45.01B
- P/E (fwd)
- -36.1
- 52-week range
- $39.17–$224.31
- Off 52-week high
- 6.2%
- RSI (14)
- 48
- Volume vs avg
- 0.50×
- Score today
- 4.8/10